#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating Department of Veterans’ Affairs clients must update medicinal cannabis treatment plans before August 31 to ensure continuity of care, as grandfathering arrangements expire and patients will need to transition to current regulatory pathways. Failure to review and modify existing prescriptions could result in treatment interruption for veterans currently using cannabis therapeutically, requiring immediate action to maintain symptom management and prevent care gaps. This administrative deadline directly impacts clinical outcomes for eligible patients relying on established cannabis regimens for conditions like chronic pain and PTSD.
Veterans Affairs (DVA) clients currently receiving medicinal cannabis under grandfathering arrangements have until August 31st to transition their treatment plans to comply with updated regulatory requirements. Clinicians treating DVA patients must urgently review existing cannabis prescriptions and documentation to ensure continuity of care beyond the deadline, as patients may otherwise lose access to their current cannabis-based treatments. This regulatory change requires clinicians to reassess whether patients’ cannabis use aligns with current prescribing guidelines and to update treatment plans accordingly, potentially involving new authorization processes or alternative therapeutic approaches. For patients stable on grandfathered cannabis regimens, this transition period presents an opportunity to formalize their treatment plans with contemporary clinical documentation and ensure compliance with evolving standards. Clinicians should proactively contact their DVA clients to discuss the upcoming deadline and begin the necessary administrative and clinical work to maintain uninterrupted access to medicinal cannabis therapy where clinically appropriate.
“This administrative deadline reminds us that we need to have thoughtful conversations with our patients currently on grandfathered cannabis regimens about what the evidence actually supports and what their options are going forward, rather than letting bureaucratic transitions drive clinical decisions.”
🩺 As grandfathering arrangements for medicinal cannabis expire on August 31, clinicians caring for Department of Veterans’ Affairs clients should begin systematic review of active cannabis treatment plans to ensure continuity of care and regulatory compliance. The transition may create administrative complexity, particularly for patients whose conditions have stabilized on cannabis-based therapies, as renewed prescriptions will need to navigate current authorization pathways that may differ from the original grandfathered status. Clinicians should be aware that evidence supporting cannabis efficacy remains limited and condition-dependent, with robust data primarily in neuropathic pain and chemotherapy-induced nausea, while documentation standards and indication appropriateness may be scrutinized more closely during re-authorization. A practical next step is to audit your veteran patient population currently on medicinal cannabis, document clear clinical rationale for continued use, and initiate early conversations with patients about potential treatment adjustments or alternative options, allowing adequate time before
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
